Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05712161 · ClinicalTrials.gov registry record · NA

Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study

A NA study of Aortic Stenosis and Symptomatic Aortic Stenosis, sponsored by Anteris Technologies.

Active
Registry status
NA
Development phase
15
Enrollment target
5
Study locations

NCT05712161 is a NA study of Aortic Stenosis and Symptomatic Aortic Stenosis that is active but no longer recruiting, run by Anteris Technologies. The registered enrollment target is 15 participants, below the 1,362-participant average among 26 other Aortic Stenosis trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05712161, a NA study of Aortic Stenosis and Symptomatic Aortic Stenosis, is active but no longer recruiting, sponsored by Anteris Technologies.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
5
Study locations

Study Summary

To evaluate the safety and feasibility of DurAVR™ THV System in the treatment of subjects with symptomatic severe native aortic stenosis.

Interventions

  • DEVICE DurAVRTM THV System

Study Locations (5)

New York

  • Columbia University Medical Center/NYPH - New York
  • Montefiore Medical Center - The Bronx

Arizona

  • Tucson Medical Center - Tucson

Michigan

  • University of Michigan - Ann Arbor

Ohio

  • Cleveland Clinic Foundation - Cleveland

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2023-08-07
Est. Completion 2033-12
Phase NA

Sponsor

Anteris Technologies

2 total trials

What the Registry Record Tells You About NCT05712161

The ClinicalTrials.gov registry entry for NCT05712161 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,362-participant average among 26 other Aortic Stenosis trials with a reported enrollment target (99% lower). The listed sponsor is Anteris Technologies, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Aortic Stenosis appearing as the primary indexed condition, and to 1 intervention - of which DurAVRTM THV System is the first listed.

NCT05712161 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New York, Arizona, Michigan.

Frequently Asked Questions

What is clinical trial NCT05712161 about?

NCT05712161 is a clinical study titled "Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study". To evaluate the safety and feasibility of DurAVR™ THV System in the treatment of subjects with symptomatic severe native aortic stenosis.

What is the current status of trial NCT05712161?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2023-08-07. Estimated completion is 2033-12.

What conditions does trial NCT05712161 study?

This clinical trial studies the following conditions: Aortic Stenosis, Symptomatic Aortic Stenosis, Aortic Valve Calcification, Severe Aortic Valve Stenosis.

What interventions are being tested in trial NCT05712161?

The interventions under investigation include: DurAVRTM THV System (DEVICE).

Who is sponsoring clinical trial NCT05712161?

This trial is sponsored by Anteris Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05712161 being conducted?

This trial has 5 study locations across Arizona, Michigan, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aortic Stenosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.